Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PfSPZ Challenge (NF54 vs 7G8) Infectivity Study
NCT04203186Phase 1Withdrawn
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Mar 2020
- Primary completion
- Jun 2021
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, double-blind trial of PfSPZ Challenge in malaria (2 arms), sponsored by U.S. Army Medical Research and Development Command. Primary endpoints: Difference in the pre-patent period at 29 days and Difference in the total number of malaria events at 29 days. Planned start Mar 2020; status: withdrawn.
02
Drugs
PfSPZ Challenge
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04203186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04203186.